Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
Stopped Slow enrollment and minimal preliminary biological and clinical efficacy.
Conditions
- Chronic Lymphocytic Leukemia
Interventions
Sponsor
Novartis Pharmaceuticals
Collaborators